- Home
- SNX vs SLRX Comparison
SNX vs SLRX Comparison
Compare SNX & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNX | SLRX |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 3.6M |
| IPO Year | 2003 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNX | SLRX |
|---|---|---|
| Price | $152.40 | $0.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $168.60 | N/A |
| AVG Volume (30 Days) | ★ 786.4K | 341.4K |
| Earning Date | 01-08-2026 | 11-14-2025 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | ★ 18.98 | N/A |
| EPS | ★ 9.21 | N/A |
| Revenue | ★ $60,973,509,000.00 | N/A |
| Revenue This Year | $7.25 | N/A |
| Revenue Next Year | $4.35 | N/A |
| P/E Ratio | $16.63 | ★ N/A |
| Revenue Growth | ★ 6.94 | N/A |
| 52 Week Low | $92.23 | $0.51 |
| 52 Week High | $167.76 | $108.00 |
Technical Indicators
Market Signals| Indicator | SNX | SLRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 34.09 |
| Support Level | $149.96 | $0.51 |
| Resistance Level | $157.14 | $0.68 |
| Average True Range (ATR) | 2.90 | 0.06 |
| MACD | -0.09 | 0.06 |
| Stochastic Oscillator | 50.37 | 40.81 |
Price Performance
Historical ComparisonAbout SNX TD SYNNEX Corporation
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.